Trial Profile
A Phase II Study of Anti-PD-1 (Pembrolizumab) in Combination With Hormonal Therapy During or After Radiation in Patients With Hormone Receptor (HR)-Positive Localized Inflammatory Breast Cancer (IBC) Who Did Not Achieve a Pathological Complete Response (pCR) to Neoadjuvant Chemotherapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 21 Jan 2024
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Anastrozole; Exemestane; Letrozole; LHRH receptor agonists; Tamoxifen
- Indications Carcinoma; Inflammatory breast cancer; Male breast cancer
- Focus Therapeutic Use
- 22 Jun 2022 Status changed from recruiting to active, no longer recruiting.
- 24 Jan 2022 Planned End Date changed from 31 Dec 2021 to 31 Dec 2024.
- 24 Jan 2022 Planned primary completion date changed from 31 Dec 2021 to 31 Dec 2024.